Human and Improved Murine Monoclonal Antibodies Against CD22
Summary:
Researchers at the NCI seek research and co-development partners and/or licensing for the development of human monoclonal antibodies and antibody-based therapeutics against CD22.
Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection
Summary:
Inventors are seeking licensing and/or co-development research collaborations for a unique novel molecular Adjuvanted Mucosal Subunit Vaccine to prevent SARS-CoV-2 transmission and infection.
Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging
Summary:
Researchers at UCI and NCI seek licensing to adopt new applications for a family of far-red to near-infrared emission coumarin-based luciferins (CouLuc) with complementary mutant enzymes.
Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis
Summary:
The NIA seeks co-development partners and/or licensees for the further development of Cα-peptide as a therapeutic that inhibits islet amyloidosis.
Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease
Summary:
The NICHD is seeking licensees for development of Carboxypeptidase E (CPE) as a therapy for MCI or AD.
Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics
Summary:
NICHD is seeking research co-development partners and/or licensees for development of this invention as a male contraceptive.
Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a)
Summary:
NICHD is seeking licensees for development of an adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).
Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens
Description of Technology:
Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL.
A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma
Summary:
NCI seeks proposals from parties interested in co-development and licensing opportunities to employ biomarker viral exposure signature in diagnostic assays of early onset HCC.
T-Cell Therapy Against Patient-Specific Cancer Mutations
Description of Technology:
Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets.